AR124977A1 - Composiciones y métodos para reducir la expresión de citocinas - Google Patents

Composiciones y métodos para reducir la expresión de citocinas

Info

Publication number
AR124977A1
AR124977A1 ARP220100419A ARP220100419A AR124977A1 AR 124977 A1 AR124977 A1 AR 124977A1 AR P220100419 A ARP220100419 A AR P220100419A AR P220100419 A ARP220100419 A AR P220100419A AR 124977 A1 AR124977 A1 AR 124977A1
Authority
AR
Argentina
Prior art keywords
compositions
expression
methods
cytokines
reduce
Prior art date
Application number
ARP220100419A
Other languages
English (en)
Inventor
David Epstein
Duncan Mchale
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR124977A1 publication Critical patent/AR124977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos y composiciones relacionados con vesículas extracelulares (VE) de Prevotella histicola y soluciones y formas secas (y composiciones terapéuticas de las mismas) de vesículas extracelulares (VE) de Prevotella histicola para la reducción de la expresión de IL-8, IL-6, IL-1b y/o TNFa y/o para el tratamiento de infecciones víricas.
ARP220100419A 2021-02-26 2022-02-25 Composiciones y métodos para reducir la expresión de citocinas AR124977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163154218P 2021-02-26 2021-02-26

Publications (1)

Publication Number Publication Date
AR124977A1 true AR124977A1 (es) 2023-05-24

Family

ID=80820172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100419A AR124977A1 (es) 2021-02-26 2022-02-25 Composiciones y métodos para reducir la expresión de citocinas

Country Status (5)

Country Link
US (1) US20240148797A1 (es)
EP (1) EP4297762A1 (es)
AR (1) AR124977A1 (es)
TW (1) TW202245736A (es)
WO (1) WO2022182707A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
AU2004287373A1 (en) 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US8617536B2 (en) * 2009-10-30 2013-12-31 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
CN105142616B (zh) 2013-03-01 2018-02-13 Bpsi控股有限责任公司 含有硅酸钙的延迟释放薄膜包衣及其包被的底物
BR112020004347A2 (pt) * 2017-09-08 2020-09-08 Evelo Biosciences, Inc. vesículas extracelulares de prevotella
MA50086A (fr) * 2017-09-08 2020-07-15 Evelo Biosciences Inc Vésicules extracellulaires (ev) bactériennes
CA3143597A1 (en) * 2019-06-17 2020-12-24 Mayo Foundation For Medical Education And Research Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions
CN114245742A (zh) * 2019-06-21 2022-03-25 伊夫罗生物科学公司 使用普雷沃菌属治疗th2介导的病症的组合物和方法
AU2021227972A1 (en) * 2020-02-26 2022-09-29 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
CN115551486A (zh) * 2020-04-17 2022-12-30 伊夫罗生物科学公司 具有改善的崩解谱的固体剂型

Also Published As

Publication number Publication date
US20240148797A1 (en) 2024-05-09
WO2022182707A1 (en) 2022-09-01
EP4297762A1 (en) 2024-01-03
TW202245736A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CO2021012176A2 (es) Preparaciones de membrana bacteriana
CL2021003098A1 (es) Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon (divisional de la solicitud no. 202100061)
MX2022010542A (es) Composiciones y metodos para reducir la expresion de citocinas.
CO2021007908A2 (es) Derivados de oxopiridina sustituidos
ECSP20082988A (es) Agonistas de tlr7
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
EA202190261A1 (ru) Топические маслянистые композиции
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
CL2020003169A1 (es) Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia
CO2024007013A2 (es) Isoxazolidinas como inhibidores de ripk1 y uso de estas
AR124977A1 (es) Composiciones y métodos para reducir la expresión de citocinas
FR3075012B1 (fr) Procede de traitement cosmetique par plasma froid
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
CO2022008835A2 (es) Agonistas del tlr7
AR121405A1 (es) Composiciones y métodos para reducir la expresión de citocinas
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
CO2023012462A2 (es) Fabricación y uso de vectores aav recombinantes
AR123554A1 (es) Composiciones y métodos para el tratamiento de la inflamación usando prevotella histicola
AR129545A1 (es) Composición, método y usos de la misma
UY38482A (es) Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas
CL2022002375A1 (es) Soluciones antimicrobianas y métodos de uso de estas en el tratamiento o prevención de infecciones
AR117132A1 (es) Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure